Carson Wealth (CWM LLC)’s Galectin Therapeutics GALT Stock Holding History

Carson Wealth (CWM LLC)’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$388	Sell	139 -167	-55%	-$508	﹤0.01%	5476
2025 Q4	$1K	Sell	306 -24	-7%	-$126	﹤0.01%	5217
2025 Q3	$1K	Sell	330 -929	-74%	-$3.5K	﹤0.01%	5120
2025 Q2	$3K	Buy	1,259 +511	+68%	+$765	﹤0.01%	4764
2025 Q1	$1K	Buy	748 +675	+925%	+$947	﹤0.01%	4904
2024 Q4	$0	Sell	73 -97	-57%	-$232	﹤0.01%	4991
2024 Q3	$0	Buy	+170	New	+$417	﹤0.01%	4926
2019 Q1	–	Sell	-2,000	Closed	-$7K	–	3066
2018 Q4	$7K	Hold	2,000	–	–	﹤0.01%	1440
2018 Q3	$12K	Hold	2,000	–	–	﹤0.01%	1104
2018 Q2	$13K	Buy	+2,000	New	+$9.74K	﹤0.01%	929

Other funds holding GALT

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Carson Wealth (CWM LLC)'s GALT Position: Q1 2026 in Review

Carson Wealth (CWM LLC) reduced its Galectin Therapeutics (GALT) stake by 55% in Q1 2026, selling an estimated $508 and leaving 139 shares worth $388. The position accounts for ﹤0.01% of the portfolio, ranked #5476.

Carson Wealth (CWM LLC) first reported a position in GALT in Q2 2018 and has held it in 10 quarters since. The position peaked at $13K in Q2 2018. 99 funds tracked by Wall St. Rank hold GALT as of Q1 2026.

Carson Wealth (CWM LLC) held 139 shares of Galectin Therapeutics worth $388 as of Q1 2026.
Carson Wealth (CWM LLC) sold 167 Galectin Therapeutics shares in Q1 2026, an estimated $508.
Galectin Therapeutics made up ﹤0.01% of Carson Wealth (CWM LLC)'s portfolio in Q1 2026, its #5476 holding.
Carson Wealth (CWM LLC) first reported a position in Galectin Therapeutics in Q2 2018 and has held it in 10 quarters since.
Carson Wealth (CWM LLC)'s Galectin Therapeutics position peaked at $13K in Q2 2018.
99 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q1 2026.

Based on Carson Wealth (CWM LLC)'s 13F filing for Q1 2026, filed 14 May 2026.